Concurrently with the inhibition of the neuronal ISR, the second element of the composite therapeutic strategy for symptomatic AD is engaged: the activation of intra-iAβ cleaving capabilities of BACE1 and/or BACE2. This evidence concerns the gene BACE1 and Alzheimer disease.